Reuters logo
BRIEF-Selecta Biosciences commences dosing in Phase 1 clinical trial of nicotine vaccine for smoking cessation and relapse prevention
2017年5月11日 / 晚上8点13分 / 4 个月前

BRIEF-Selecta Biosciences commences dosing in Phase 1 clinical trial of nicotine vaccine for smoking cessation and relapse prevention

May 11 (Reuters) - Selecta Biosciences Inc

* Selecta Biosciences commences dosing in Phase 1 clinical trial of nicotine vaccine for smoking cessation and relapse prevention Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below